Fingerprint
Dive into the research topics of 'Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek
Research output: Contribution to journal › Article › peer-review
68
Scopus
citations